Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 2/20 | 0.70 |
| ▸ | IMPDH2 | P12268 | 7/20 | 0.67 |
| ▸ | TGM2 | P21980 | 1/20 | 0.65 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.65 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.63 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.63 |
| ▸ | KRAS | P01116 | 5/20 | 0.61 |
| ▸ | CA5A | P35218 | 1/20 | 0.60 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.58 |
| ▸ | HINT1 | P49773 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26067722 | 1.00 | NT5E (0.70) | NT5EIMPDH2TGM2IMPDH1TAS1R3 | |
| SCHEMBL11895338 | 0.92 | TGM2 (0.70) | NT5EIMPDH2TGM2IMPDH1KRAS | |
| SCHEMBL15747233 | 0.92 | TGM2 (0.70) | NT5EIMPDH2TGM2IMPDH1KRAS | |
| SCHEMBL1526660 | 0.92 | TGM2 (0.70) | NT5EIMPDH2TGM2IMPDH1KRAS | |
| E626 SCHEMBL5854 | 0.92 | NT5E (0.83) | NT5EIMPDH2TGM2IMPDH1TAS1R3 | |
| E626 SCHEMBL21803790 | 0.92 | NT5E (0.83) | NT5EIMPDH2TGM2IMPDH1TAS1R3 | |
| E626 SCHEMBL21163348 | 0.92 | NT5E (0.83) | NT5EIMPDH2TGM2IMPDH1TAS1R3 | |
| E626 SCHEMBL20677331 | 0.92 | NT5E (0.83) | NT5EIMPDH2TGM2IMPDH1TAS1R3 | |
| E626 SCHEMBL18785103 | 0.92 | NT5E (0.83) | NT5EIMPDH2TGM2IMPDH1TAS1R3 | |
| E626 SCHEMBL13497991 | 0.92 | NT5E (0.83) | NT5EIMPDH2TGM2IMPDH1TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119614654-A | Enzymatic synthesis method of 2' -fluoro-2 ' -deoxynucleoside-5 ' -triphosphate and application thereof | 华南理工大学 | 2025-03-14 | — | — | CN | disclosed |
| US-20210189393-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF FACTOR V | ALNYLAM PHARMACEUTICALS, INC. | 2021-06-24 | — | — | US | disclosed |
| EP-3578656-B1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE PCSK9 GENE | ALNYLAM PHARMACEUTICALS INC (US) | 2021-01-06 | — | — | EP | disclosed |
| EP-3693463-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | Alnylam Pharmaceuticals, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| US-20200231968-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF FACTOR V | ALNYLAM PHARMACEUTICALS, INC. | 2020-07-23 | — | — | US | disclosed |
| EP-3052628-B1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | ALNYLAM PHARMACEUTICALS INC (US) | 2020-02-26 | — | — | EP | disclosed |
| EP-3249052-B1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE PCSK9 GENE | ALNYLAM PHARMACEUTICALS INC (US) | 2019-04-10 | — | — | EP | disclosed |
| US-10119143-B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-11-06 | — | — | US | disclosed |
| US-20180127749-A1 | Compositions and Methods for Inhibiting Expression of Factor V | BANK OF AMERICA, N.A. | 2018-05-10 | — | — | US | disclosed |
| EP-3249052-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE PCSK9 GENE | Alnylam Pharmaceuticals, Inc. (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20080113930-A1 | an RNA strand (the antisense strand) having a region which is less than 30 nucleotides in length, complementary to at least a part of the PCSK9 gene; antihyperlipemia agent | BANK OF AMERICA, N.A. | 2008-05-15 | — | — | US | disclosed |
| US-20080113931-A1 | RNAi MODULATION OF AHA AND THERAPEUTIC USES THEREOF | SCRIPPS RESEARCH INSTITUTE, THE | 2008-05-15 | — | — | US | disclosed |
| US-20080108584-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF IKK-B GENE | BANK OF AMERICA, N.A. | 2008-05-08 | — | — | US | disclosed |
| US-7320965-B2 | Double-stranded ribonucleic acid (dsRNA), mediating RNA interference, Huntington's disease | ALNYLAM PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-20070281899-A1 | double-stranded ribonucleic acid comprises a sense strand first sequence and an antisense strand second sequence; modified; as a biodrug for treating diseases caused by Eg5 expression; as anticarcinogenic agent for treating cancer; selectively and efficiently silence the Eg5 gene | ALNYLAM PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070105806-A1 | Compositions and methods for inhibiting expression of Nav1.8 gene | ALNYLAM EUROPE AG (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070099860-A1 | Double-stranded ribonucleic acid (dsRNA), mediating RNA interference, Huntington's disease | MEDTRONIC, INC. | 2007-05-03 | — | — | US | disclosed |
| US-20060105976-A1 | RNAi modulation of ApoB and uses thereof | BANK OF AMERICA, N.A. | 2006-05-18 | — | — | US | disclosed |
| US-20060094678-A1 | Nuclease resistant double-stranded ribonucleic acid | BANK OF AMERICA, N.A. | 2006-05-04 | — | — | US | disclosed |
| US-20060084621-A1 | Compositions and methods for inhibiting expression of anti-apoptotic genes | ALNYLAM PHARMACEUTICALS, INC. | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210189393-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF FACTOR V | F5, F13B, F13A1 | NT5E 589/4885IMPDH2 2730/4885TGM2 2899/4885 |
| US-20080113931-A1 | RNAi MODULATION OF AHA AND THERAPEUTIC USES THEREOF | AHSA1, MTREX, RNASEH1 | NT5E 2072/4885IMPDH2 747/4885TGM2 2928/4885 |
| US-20060105976-A1 | RNAi modulation of ApoB and uses thereof | APOB, LDLR, APOL1 | NT5E 2183/4885IMPDH2 4319/4885TGM2 3550/4885 |
| US-20070281899-A1 | double-stranded ribonucleic acid comprises a sense strand first sequence and an antisense strand second sequence; modified; as a biodrug for treating diseases caused by Eg5 expression; as anticarcinogenic agent for treating cancer; selectively and efficiently silence the Eg5 gene | GEMIN5, RNASE1, EFTUD2 | NT5E 307/4885IMPDH2 1294/4885TGM2 547/4885 |
| US-20080108584-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF IKK-B GENE | IKBKG, IKBKB, NFKBIA | NT5E 2076/4885IMPDH2 1877/4885TGM2 3963/4885 |
| US-20060084621-A1 | Compositions and methods for inhibiting expression of anti-apoptotic genes | BAX, BCL2, API5 | NT5E 1482/4885IMPDH2 2304/4885TGM2 3862/4885 |
| US-20060094678-A1 | Nuclease resistant double-stranded ribonucleic acid | RNASE1, RNASEH1, RNASEL | NT5E 465/4885IMPDH2 480/4885TGM2 3201/4885 |
| US-20070099860-A1 | Double-stranded ribonucleic acid (dsRNA), mediating RNA interference, Huntington's disease | HTT, HYPK, DHX36 | NT5E 1330/4885IMPDH2 1685/4885TGM2 2945/4885 |
| US-20200231968-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF FACTOR V | F5, F13B, F13A1 | NT5E 589/4885IMPDH2 2730/4885TGM2 2899/4885 |
| US-10119143-B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | AARS1, RNASE1, DDX39B | NT5E 2411/4885IMPDH2 758/4885TGM2 977/4885 |
| US-20180127749-A1 | Compositions and Methods for Inhibiting Expression of Factor V | F5, F13B, F13A1 | NT5E 589/4885IMPDH2 2730/4885TGM2 2899/4885 |
| US-20070105806-A1 | Compositions and methods for inhibiting expression of Nav1.8 gene | SCN8A, SCN7A, SCN5A | NT5E 170/4885IMPDH2 1730/4885TGM2 4543/4885 |
| US-20080113930-A1 | an RNA strand (the antisense strand) having a region which is less than 30 nucleotides in length, complementary to at least a part of the PCSK9 gene; antihyperlipemia agent | PCSK9, PCSK7, PCSK6 | NT5E 991/4885IMPDH2 1819/4885TGM2 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.